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Abstract
Background: A proportion of patients with acute ischemic stroke have elevated cardiac troponin levels and
ECG changes suggestive of cardiac injury, but the etiology is unclear. The aims of this study were to assess the
frequency of high sensitivity cardiac troponin T (hs-cTnT) elevation, to identify determinants and ECG changes
associated with hs-cTnT elevation, to identify patients with myocardial ischemia and to assess the impact of
hs-cTnT elevation on in-hospital mortality.
Methods: Patients discharged with a diagnosis of acute ischemic stroke during a 1-year period, were included.
Patients diagnosed with acute myocardial infarction (MI) within the last 7 days before admission or during
hospitalization were excluded.
Results: In all, 156 (54.4%) of 287 patients had elevated hs-cTnT. The factors independently associated with hs-cTnT
elevation were age≥ 76 years (OR 3.71 [95% CI 2.04-6.75]), previous coronary heart disease (CHD) (OR 2.61 [1.23-5.53]),
congestive heart failure (OR 4.26 [1.15-15.82]), diabetes mellitus (OR 4.02 [1.50-10.76]) and lower eGFR (OR 0.97 [0.95-0.98]).
Of the 182 patients who had two hs-cTnT measurements, 12 (6.6%) had both a rise or fall of hs-cTnT with at least one
elevated value, and ECG manifestations of myocardial ischemia, e.g. meeting the criteria of acute MI. Both dynamic
relative change (p = 0.026) and absolute change (p = 0.032) in hs-cTnT were significantly associated with higher
in-hospital mortality.
Conclusions: Established CHD and cardiovascular risk factors are associated with hs-cTnT elevation. Acute MI is likely
underdiagnosed in acute ischemic stroke patients. Dynamic changes in troponin levels seem to be related to poor
short-term prognosis.
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Background
Cardiac troponins are sensitive and specific markers of
myocardial necrosis, and are measured routinely in the
diagnosis of acute myocardial infarction (MI). The uni-
versal definition of acute MI requires detection of rise
and/or fall of cardiac biomarker values (preferably car-
diac troponin) with at least one value above the 99th per-
centile of the upper reference limit [1]. The highly
sensitive troponin assays meet the analytical criteria re-
quired, as they have a limit of detection lower than the
99th percentile of a general population, and a coefficient
of variation of 10% or less at this concentration [2]. The
National Academy of Clinical Biochemistry has recom-
mended the use of δ 20% in sensitive assays when car-
diac troponin is above the 99th percentile [3,4], while
Mueller et al [5] have proposed the use of an absolute
change of at least 9.2 ng/L. In acute MI, values may re-
main elevated for two weeks or more following the onset
of myocardial necrosis [1].
More widespread use of the highly sensitive assays
have led to substantial increase in the detection of ele-
vated levels of cardiac troponin, even among patients ad-
mitted for other conditions [6], such as end-stage renal
disease (ESRD) [3,7], pulmonary embolism (PE) [8] and
epileptic seizures [9]. Several studies have shown eleva-
tion of markers of myocardial damage in a proportion of
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patients with acute stroke [10-13], and elevated levels
are associated with mortality [11,13,14]. In a systematic
review [15], the prevalence of cardiac troponin elevation
in stroke patients was reported to vary from 0 to 34%,
but the studies reviewed were heterogeneous and diffi-
cult to compare due to different troponin assays and
cut-offs. Furthermore, it is uncertain whether this eleva-
tion is transient or chronic and whether the etiology is
acute myocardial ischemia or comorbidities. In addition,
stroke patients often manifest electrocardiography (ECG)
changes suggestive of cardiac injury [16,17], but the eti-
ology is unclear.
The aims of the present study were to identify possible
determinants associated with high sensitivity cardiac
troponin T (hs-cTnT) elevation and to determine the
prevalence of ECG changes in patients with acute ische-
mic stroke. In addition, we wanted to examine whether
hs-cTnT values on admission or dynamic changes in hs-
cTnT are related to in-hospital mortality.
Methods
In this retrospective study, all patients aged 18 and above,
discharged from Department of Neurology, Akershus Uni-
versity Hospital, with a diagnosis of acute ischemic stroke
(ICD-10 I63.x [International Classification of Diseases,
10th revision]) between June 1, 2009 and May 31, 2010,
were identified by a systematic search in our clinical data-
base. In the case of multiple admissions during the study
period, only the first admission was included. Patients ad-
mitted from other hospitals were excluded because of in-
complete data. In this patient cohort, we have previously
shown admission hs-cTnT levels to be a predictor of all-
cause mortality [14].
In total, 367 patients were identified. In the present
study, patients were excluded if admission was delayed
more than 24 hours after symptom onset (n = 61), if they
were diagnosed with acute MI within the last 7 days
before admission or during hospitalization (n = 16), or if
they were diagnosed with acute PE during hospitalization
(n = 3). Patients with a diagnosis of ESRD requiring dialy-
sis were not eligible (n = 0).
Patient characteristics were extracted by chart review
and included age, gender and history of cerebrovascular
disease (CVD), coronary heart disease (CHD), congestive
heart failure, atrial fibrillation, diabetes mellitus, smok-
ing, hypertension and hyperlipidemia. Stroke severity
was determined using the National Institutes of Health
Stroke Scale (NIHSS) [18]. Values regarding pulse and
blood pressure (BP) were registered, and it was recorded
whether the patients received intravenous thrombolytic
therapy with recombinant tissue plasminogen activator
(rt-PA). Stroke etiology was classified according to the
Trial of ORG 10172 in Acute Stroke Treatment (TOAST)
criteria [19].
Serum concentrations of hs-cTnT were routinely mea-
sured on admission and the following morning (up to
24 hours after the first measurement), or earlier at the
discretion of the physician on call. The hs-cTnT analyses
were performed using a commercially available assay
(Roche Diagnostics, Mannheim, Germany). The limit of
detection (LoD) was 5 ng/L (pg/mL), and values under
this limit were routinely classified as 4.99 ng/L. Accord-
ing to the manufacturer, the upper reference limit (URL;
the 99th percentile in a normal reference population) was
14 ng/L. Recently, gender specific 99th percentiles have
been published [20]; 13 ng/L in females and 20 ng/L in
males.
Biochemical analyses for blood leukocyte count and
estimated glomerular filtration rate (eGFR) were per-
formed on admission. eGFR was estimated using the
Modification of Diet in Renal Disease (MDRD) formula.
Standard 12-lead ECGs recorded on admission were
evaluated by two investigators (GE and PHB), blinded
for patient data. Inter-observer differences were resolved
by consensus. The following ECG parameters were ana-
lyzed: heart rate and rhythm, PR interval, QRS interval,
QTc interval, Q wave, ST segment elevation and/ or de-
pression [21], T-wave inversion [21], Sokolow-Lyon volt-
age [22] and the Cornell product [23]. The definitions of
the ECG parameters are presented in Additional file 1:
Table S1. Electrocardiographic left ventricular hyper-
trophy (LVH) was defined as fulfilling the Sokolow-Lyon
voltage and/or the Cornell product criteria. Only heart
rate and rhythm were evaluated in patients with pace-
makers. PR interval was not evaluated in patients with
atrial fibrillation/flutter. Sokolow Lyon voltage and the
Cornell product were not evaluated in patients with left
bundle branch block (LBBB). ST segment elevation, ST
segment depression and T-wave inversion were not eval-
uated in patients with LBBB or LVH.
In-hospital mortality was used as the outcome measure.
Statistical analysis
Continuous variables are presented as mean values and
standard deviation (SD) for normally distributed data
and as median values and interquartile range (IQR) for
non-normally distributed data. Normality was tested
using normality Q-Q plots and Kolmogorov-Smirnov
analysis. Categorical variables are presented in absolute
values and percentages.
As most variables were not normally distributed, com-
parisons between groups were made by Mann-Whitney
U-test for continuous variables, and Pearson’s χ2-test or
Fisher’s exact test for categorical variables (as appropri-
ate). Elevated hs-cTnT was defined as > 14 ng/L (higher
than the URL). Spearman’s rank correlation analysis was
performed to assess the correlation between hs-cTnT
and age and eGFR.
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Multivariate logistic regression analysis was performed
to identify determinants independently associated with
elevated hs-cTnT. Variables associated with hs-cTnT
elevation in the univariate analyses with a p-value <0.20
were included in the multivariate analysis. In addition,
we performed gender specific multivariate logistic re-
gression analyses using the gender specific 99th percent-
ile values and multivariate linear regression analysis
in the entire study population with hs-cTnT as the
dependent variable (logarithmically transformed con-
tinuous variable because of a non-normal distribution).
Furthermore, multivariate logistic regression analyses
were performed to assess whether elevated hs-cTnT on
admission or dynamic changes in hs-cTnT were related
to in-hospital mortality. Dynamic changes were assessed
as i) relative change (percent δ between two measure-
ments with a predefined cut point of 20%); ii) absolute
change (δ between two measurements with a predefined
cut point of 9.2 ng/L).
Age was dichotomized to higher or lower than the me-
dian age in the multivariate analyses.
Associations are presented as odds ratios (OR) with
the corresponding 95% CI. A p-value <0.05 was consid-
ered to be statistically significant. All statistical analyses
were performed using SPSS statistical software version
18 (SPSS Inc, Chicago, IL, USA).
The study was approved by the Regional Committee
for Ethics in Medical Research.
Results
A total of 287 patients were included in the study, with
a median age of 76 years (IQR 65-83), and 44.9% were
females. Patient characteristics are shown in Table 1.
The hs-cTnT concentration on admission was available
for all patients, while two hs-cTnT measurements were
available for 264 (92.0%) patients. The median hs-cTnT
concentration on admission was 15.6 ng/L (IQR 7.7-
28.5). Admission hs-cTnT was above the LoD in 249
Table 1 Patient characteristics
All patients hs-cTnT ≤14 ng/L hs-cTnT > 14 ng/L p value
(n = 287) (n = 131) (n = 156)
Age (y) 76 (65–83) 65 (59–76) 81 (74–87) <0.001
Females 129 (44.9) 59 (45.0) 70 (44.9) 0.977
Medical history:
Cerebrovascular disease 61 (21.3) 18 (13.7) 43 (27.6) 0.004
Coronary heart disease 72 (25.1) 15 (11.5) 57 (36.5) <0.001
Congestive heart failure 33 (11.5) 4 (3.1) 29 (18.6) <0.001
Atrial fibrillation 79 (27.5) 20 (15.3) 59 (37.8) <0.001
Diabetes mellitus 39 (13.6) 10 (7.6) 29 (18.6) 0.007
Smoking 53 (18.5) 36 (27.5) 17 (10.9) <0.001
Hypertension 179 (62.4) 67 (51.1) 112 (71.8) <0.001
Hyperlipidemia 86 (30.0) 35 (26.7) 51 (32.7) 0.271
Vital signs:
Pulse 77.4 (±17.3) 76.8 (±15.1) 78.0 (±19.0) 0.818
Systolic BP 165.9 (±30.3) 167.9 (±29.5) 164.3 (±30.9) 0.337
Diastolic BP 87.1 (±15.0) 88.1 (±13.2) 86.2 (±16.3) 0.152
NIHSS 4 (2-9) 3 (1-7) 4 (2-12) 0.001
rt-PA 27 (9.4) 21 (16.0) 6 (3.8) <0.001
Blood leukocyte count (109/L) 7.6 (6.4-9.8) 7.6 (6.0-9.6) 7.6 (6.6-9.8) 0.276
eGFR (mL/min) 71.0 (±21.8) 79.4 (±19.4) 63.9 (±21.3) <0.001
TOAST
Small vessel 65 (22.6) 37 (28.2) 28 (17.9) 0.038
Large artery 51 (17.8) 23 (17.6) 28 (17.9) 0.931
Cardioembolic 84 (29.3) 20 (15.3) 64 (41.0) <0.001
Other/ undetermined 87 (30.3) 51 (38.9) 36 (23.1) 0.004
Categorical variables are presented in absolute values with percentages; n (%). Continuous variables are presented as mean (±SD) or median with
interquartile range.
hs-cTnT: high sensitivity cardiac troponin T; BP: blood pressure; NIHSS: National Institute of Health Stroke Scale; rt-PA: recombinant tissue plasminogen activator;
eGFR: estimated glomerular filtration rate; TOAST: Trial of ORG 10172 in Acute Stroke Treatment.
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(86.8%) patients and elevated in 156 (54.4%) patients.
Using the gender specific 99th percentile values, hs-cTnT
was elevated in 71 (55.0%) females and 65 (41.1%) males.
Elevation of hs-cTnT in the entire study population
was associated with older age (p < 0.001), history of
CVD (p = 0.004) and CHD (p < 0.001), congestive heart
failure (p < 0.001), atrial fibrillation (p < 0.001), diabetes
mellitus (p = 0.007), non-smoking (p < 0.001) and hyper-
tension (p < 0.001) in the univariate analyses. Patients
with elevated hs-cTnT had more severe strokes (p = 0.001)
and worse renal function (p < 0.001). There were no sig-
nificant differences regarding pulse and BP.
The median value of the second hs-cTnT concentra-
tion was 16.9 ng/L (IQR 9.2-33.4). The median time
interval between the two hs-cTnT measurements was
16.0 hours (IQR 10.7-19.8).
Of the 264 patients with serial measurements, 81
(30.7%) patients had dynamic relative change greater
than 20%, while 46 (17.4%) patients had absolute change
greater than 9.2 ng/L.
The hs-cTnT level was strongly correlated to age (Spear-
man’s ρ = 0.55, p < 0.001) and eGFR (Spearman’s ρ = - 0.40,
p < 0.001).
ECG
ECGs were available for analysis in 279 (97.2%) patients.
Eight ECGs were either unreadable or missing. Additional
file 1: Figure S1 shows a flow diagram for the ECG ana-
lysis. Three patients (1.1%) had a cardiac pacemaker. Atrial
fibrillation/flutter was present in 72 (25.8%) patients, while
63 of 264 (23.9%) patients had LVH (patients with pace-
makers and LBBB excluded). Compared to patients with
hs-cTnT within the reference limit, patients with elevated
hs-cTnT more frequently had atrial fibrillation/flutter
(p < 0.001), right bundle branch block (RBBB) (p = 0.026),
ST segment depression (p = 0.025), T-wave inversion
(p = 0.029) and LVH (p = 0.019). In all, 34 of 276 (12.3%)
patients had pathological Q waves, suggestive of prior MI,
but there were no significant differences between patients
with hs-cTnT within the reference limit and elevation
(p = 0.096). The results are summarized in Table 2.
After excluding patients with pacemakers, LBBB and
LVH, a total of 47 of 201 (23.4%) patients had ECG
manifestations of myocardial ischemia (ST segment ele-
vation and/ or ST segment depression and/or T-wave in-
version). In total, 100 of the 201 (49.8%) patients had
elevated admission hs-cTnT, and 29 of 201 (14.4%) had
both ECG manifestations of myocardial ischemia and
elevated hs-cTnT on admission.
In the subgroup of patients with serial hs-cTnT values,
12 of 182 (6.6%) patients had both ECG manifestations of
myocardial ischemia and rise or fall of hs-cTnT (δ ≥ 20%)
with at least one value above the 99th percentile of the
URL.
Multivariate analyses
When the factors associated with hs-cTnT elevation in
the univariate analyses (p < 0.20) were entered into the
multivariate logistic regression analysis, the following
factors emerged as significant determinants of elevated
Table 2 Findings on admission ECG related to hs-cTnT
All patients hs-cTnT ≤14 ng/L hs-cTnT > 14 ng/L p value
Heart rate (n = 279) 71.9 (±15.5) 73.2 (±16.2) (n = 127) 76.7 (±20.2) (n = 152) 0.296
Pacemaker (n = 279) 3 (1.1) 1/127 (0.8) 2/152 (1.3) 0.996
Atrial fibrillation/ flutter (n = 276) (2) 72 (25.8) 14/127 (11.0) 58/152 (38.2) <0.001
PR interval (n = 207) (1) 173.4 (±33.0) 167.6 (±31.0) (n = 113) 180.4 (±34.1) (n = 94) 0.005
QRS duration (n = 276) (2) 103.0 (±29.3) 97.7 (±17.1) (n = 126) 107.5 (±35.9) (n = 150) 0.010
QTc interval (n = 276) (2) 416.5 (±38.2) 413.0 (±24.2) (n = 126) 419.5 (±46.7) (n = 150) 0.010
Right bundle branch block (n = 276) (2) 19 (6.9) 4/126 (3.2) 15/150 (10.0) 0.026
Left bundle branch block (n = 276) (2) 12 (4.3) 4/126 (3.2) 8/150 (5.3) 0.381
Q wave (n = 276) (2) 34 (12.3) 11/126 (8.7) 23/150 (15.3) 0.096
Left ventricular hypertrophy (n = 264) (2, 3, 4) 63 (23.9) 21/122 (17.2) 42/142 (29.6) 0.019
ST segment elevation (n = 201) (2, 3, 5) 6 (3.0) 3/101 (3.0) 3/100 (3.0) 0.990
ST segment depression (n = 201) (2, 3, 5) 29 (14.4) 9/101 (8.9) 20/100 20.0) 0.025
T-wave inversion (n = 201) (2, 3, 5) 31 (15.4) 10/101 (9.9) 21/100 (21.0) 0.029
Categorical variables are presented in absolute values with percentages; n (%). Continuous variables are presented as mean (±SD).
hs-cTnT, high sensitivity cardiac troponin T.
(1) Excluded if presence of atrial fibrillation/ flutter.
(2) Excluded if presence of pacemaker.
(3) Excluded if presence of left bundle branch block.
(4) Sokolow-Lyon voltage > 3.5 mV and/or Cornell product > 2440 mm x ms.
(5) Excluded if presence of left ventricular hypertrophy.
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hs-cTnT in the entire study population (Table 3): age ≥
76 years (OR 3.71 [95% CI 2.04-6.75], p < 0.001), previ-
ous CHD (OR 2.61 [95% CI 1.23-5.53], p = 0.013),
congestive heart failure (OR 4.26 [95% CI 1.15-15.82],
p = 0.031), diabetes mellitus (OR 4.02 [95% CI 1.50-
10.76], p = 0.006) and lower eGFR (OR 0.97 [95% CI
0.95-0.98], p < 0.001). In the multivariate linear regres-
sion analysis (Additional file 1: Table S2), the same five
factors were significantly associated with lower hs-cTnT
as a continuous variable. In the gender specific multivari-
ate logistic regression analyses (Table 3), age ≥ 76 years
and lower eGFR were significantly associated with elevated
hs-cTnT concentration in both females and males. In fe-
males, hypertension was a statistically significant deter-
minant, while previous CHD, diabetes mellitus and atrial
fibrillation emerged as significant determinants in males.
In-hospital mortality
In total, 17 (5.9%) patients died in hospital. The median
duration of hospitalization was 5 days (IQR 3-8) for
these patients. In the subgroup of 264 patients with ser-
ial hs-cTnT values, 12 patients (4.5%) died in hospital.
Both dynamic relative change (p = 0.026) and absolute
change (p = 0.032) in hs-cTnT were significantly associ-
ated with in-hospital mortality (even after adjustment for
possible confounders), whereas stable elevation of hs-
cTnT was not. The results are summarized in Table 4.
Discussion
The principal findings in this study among patients ad-
mitted with acute ischemic stroke are: i) hs-cTnT was
higher than the URL in 53.4% of the patients; ii) 6.6% of
the patients met the criteria of acute MI; iii) patients
with elevated hs-cTnT more frequently had ST segment
depression and T-wave inversion on ECG, and iv) higher
age, history of CHD and congestive heart failure, presence
of diabetes mellitus and renal dysfunction were variables
significantly associated with hs-cTnT elevation.
Both the median hs-cTnT concentration and the preva-
lence of detectable hs-cTnT were considerably higher in
this population of patients with acute ischemic stroke than
previously reported in population-based cohorts and pa-
tients with stable CHD [20,24,25]. Previously, it has been
demonstrated that elevated hs-cTnT is a predictor of 90-
day clinical outcome [26] and long-term mortality [14] in
ischemic stroke, thus it is of clinical relevance to identify
determinants of elevated hs-cTnT. In a retrospective
study, Scheitz et al [27] demonstrated that renal insuffi-
ciency, CHD, hypercholesterolemia, higher stroke severity
and insular cortex involvement were significantly associ-
ated with elevated admission cTnT levels in ischemic
stroke patients. A fourth generation assay was used to
measure cTnT. In previous studies measuring cardiac
troponin with conventional assays in patients with acute
stroke, elevated levels have been reported as high as 34%
[28]. In a meta-analysis from 2009 by Kerr et al [15], 18%
of the patients had elevated troponin level, and these pa-
tients were more likely to have ECG changes suggestive of
acute MI (OR 3.0). The present study shows that by using
a highly sensitive assay with a lower limit of detection,
more than 50% of acute ischemic stroke patients have ele-
vated levels of cardiac troponin, even after exclusion of pa-
tients diagnosed with acute MI during hospitalization or
prior to admission. Interestingly, patients with elevated
hs-cTnT more frequently had ST segment depression and
T-wave inversion, which are typical ECG manifestations of
non-ST elevation MI (NSTEMI). We did not record pa-
tient symptoms such as chest pain or shortness of breath,
but the presence of hs-cTnT elevation and ECG manifes-
tations of myocardial ischemia indicate that acute MI is
likely underdiagnosed in patients with acute ischemic
stroke, although the findings are insufficient to conclude
Table 3 Determinants of elevated hs-cTnT in acute ischemic stroke, multivariate logistic regression analysis
All patients (n = 287), Females (n = 129), Males (n = 158),
hs-cTnT > 14 hs-cTnT > 13 hs-cTnT > 20
p value OR (95% CI) p value OR (95% CI) p value OR (95% CI)
Age≥ 76 (median) <0.001 3.71 (2.04–6.75) 0.001 5.29 (1.95–14.37) 0.001 4.11 (1.78–9.54)
Coronary heart disease 0.013 2.61 (1.23–5.53) 0.152 2.50 (0.71–8.74) 0.041 2.62 (1.04–6.60)
Congestive heart failure 0.031 4.26 (1.15–15.82) 0.591 1.55 (0.32–7.59) 0.077 4.88 (0.84–28.35)
Diabetes mellitus 0.006 4.02 (1.50–10.76) 0.691 0.75 (0.18–3.18) 0.005 5.31 (1.64–17.16)
eGFR <0.001 0.97 (0.95–0.98) 0.004 0.96 (0.94–0.98) 0.013 0.98 (0.96–0.99)
Cerebrovascular disease 0.097 1.90 (0.89–4.10) 0.678 0.78 (0.24–2.53) 0.748 1.18 (0.44–3.15)
Atrial fibrillation 0.459 1.35 (0.61–2.98) 0.997 1.00 (0.29–3.44) 0.008 4.15 (1.45–11.83)
Smoking 0.459 0.75 (0.34–1.62) 0.552 1.50 (0.40–5.73) 0.282 0.54 (0.18–1.66)
Hypertension 0.221 1.46 (0.80–2.68) 0.017 3.38 (1.24–9.20) 0.358 0.68 (0.29–1.56)
NIHSS 0.148 1.03 (0.99–1.08) 0.112 1.06 (0.99–1.13) 0.822 0.99 (0.93–1.06)
eGFR: estimated glomerular filtration rate; hs-cTnT: high sensitivity cardiac troponin T; NIHSS: National Institutes of Health Stroke Scale. Significant values in bold.
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whether the ischemia has been caused by type 1 or type 2
MI [1]. Language or cognitive impairments and silent
acute MIs before or in concert with the ischemic stroke
could be possible explanations. In addition, congestive
heart failure and renal failure could be responsible for the
troponin elevation.
In a recently published study by Kral et al. [29], 36% of the
patients had hs-cTnT higher than the URL, and 22% of the
patients presented with elevated hs-cTnT with new or pre-
sumed new significant ST-T segment changes or new LBBB.
The etiology of troponin elevation in stroke is not
completely understood and still debated. It has been
suggested that elevated levels of cardiac markers in acute
stroke patients could be related to myocytolysis due to
activation of the sympathetic nervous system [30,31].
However, earlier studies have focused on patients with
subarachnoidal hemorrhage and arrhythmias. In patients
with ischemic stroke, it is difficult to assess whether
troponin elevation is due to the acute cerebral injury
exerting myocardial stress or to pre-existing comorbidi-
ties associated with troponin elevation. Previously, epi-
nephrine [12] and cortisol [28] have been associated
with troponin elevation in acute stroke, indicating an
imbalance between the parasympathetic and sympathetic
nervous system. In our study, there were no significant
differences in pulse or BP when comparing patients with
normal and elevated hs-cTnT levels. Some studies have
highlighted the association between insular cortex involve-
ment and cTnT elevation [27,32], suggesting neurologic-
ally induced myocardial injury. We did not assess the
possible role of the insular cortex in troponin elevation.
In the study by Scheitz et al. [27], elevated cTnT on
admission was an independent predictor of in-hospital
mortality, but we could not confirm that a single value
obtained on admission was independently associated
with short-term outcome However, a novel finding is
that dynamic changes in hs-cTnT levels (both relative
and absolute change) seem to predict in-hospital mortal-
ity, which may indicate that dynamic changes in tropo-
nin levels rather than stable elevation related to chronic
diseases could be related to poor short-term prognosis.
Our study has certain limitations. First, the retrospective
collection of data limits the interpretation of the results,
and prospective studies are required to confirm our find-
ings. Second, there was a variation in time between the
two hs-cTnT measurements, and the results regarding
dynamic changes should therefore be interpreted with
caution. It is recommended that blood samples for the
measurement of cardiac troponins should be drawn on
first assessment and repeated 3–6 hours later [1], while
the median time interval was 16 hours in our study. In
addition, because of the low number in-hospital mortality
events, the results from the multivariate analyses should
be considered preliminary, and larger studies are needed
to clarify this issue. Future studies should focus on stan-
dardized serial measurements of hs-cTnT concentration
to determine whether dynamic changes are related to poor
short-term prognosis. On the other hand, the strict exclu-
sion criteria excluded patients expected to have elevated
troponin levels on admission or during hospitalization.
Conclusions
We have identified determinants and ECG changes asso-
ciated with hs-cTnT elevation in patients with acute is-
chemic stroke, and this study demonstrates a possible
role of dynamic changes in hs-cTnT for prediction of in-
hospital mortality. Acute MI is likely underdiagnosed in
patients with acute ischemic stroke. These results need
to be verified in larger prospective studies.
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Table 4 Association between elevated or change in hs-cTnT and in-hospital mortality, univariate and multivariate
logistic regression analysis
p value Unadjusted OR (95% CI) P value Adjusted OR (95% CI) (1)
hs-cTnT > 14 ng/L 0.174 2.10 (0.72–6.12) 0.839 1.15 (0.17–4.22)
log hs-cTnT 0.132 1.51 (0.88–2.59) 0.668 1.21 (0.51–2.89)
δ hs-cTnT≥ 20% (2) 0.011 4.90 (1.43–16.79) 0.026 5.35 (1.22–23.54)
δ hs-cTnT≥ 9.2 ng/L (2) 0.007 4.78 (1.53–14.96) 0.032 4.77 (1.15–19.86)
(1) Adjusted for: age ≥ 76 years, gender, stroke severity (NIHSS), coronary heart disease, cerebrovascular disease, atrial fibrillation, smoking, hypertension, diabetes
mellitus, eGFR.
(2) Rise or fall with at least one value above the 99th percentile of the upper reference limit (>14 ng/L).
eGFR: estimated glomerular filtration rate; hs-cTnT: high sensitivity cardiac troponin T; NIHSS: National Institutes of Health Stroke Scale.
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